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Background & aims: Intestinal failure (IF) is not included in the list of PubMed Mesh terms, as failure is
the term describing a state of non functioning of other organs, and as such is not well recognized. No
scientiﬁc society has yet devised a formal deﬁnition and classiﬁcation of IF. The European Society for
Clinical Nutrition and Metabolism guideline committee endorsed its “home artiﬁcial nutrition and
chronic IF” and “acute IF” special interest groups to write recommendations on these issues.
Methods: After a Medline Search, in December 2013, for “intestinal failure” and “review”[Publication
Type], the project was developed using the Delphi round methodology. The ﬁnal consensus was reached
on March 2014, after 5 Delphi rounds and two live meetings.
Results: The recommendations comprise the deﬁnition of IF, a functional and a pathophysiological
classiﬁcation for both acute and chronic IF and a clinical classiﬁcation of chronic IF. IF was deﬁned as “the
reduction of gut function below the minimum necessary for the absorption of macronutrients and/orl Failure, Department of Gastroenterology, St. Orsola-Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138
Ltd and European Society for Clinical Nutrition and Metabolism. This is an open access article under the CC BY-NC-SA
/3.0/).
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PubMed search on March 15th, 2014.
1946e1959 1960e1
Intestinal failure
[general term]
0 0
Kidney failure
[MeSH Term]
393 4226
Heart failure
[MeSH Term]
2184 5141
Liver failure
[MeSH Term]
153 833
Respiratory failure
[MeSH Term]
4 3942
Abbreviations
AIF acute intestinal failure
CIF chronic intestinal failure
CIPO chronic idiopathic pseudo-obs
EC enterocutaneous
ESPEN European Society for Clinical N
Metabolism
IF intestinal failure
ITx intestinal transplantation
HAN&CIFhome artiﬁcial nutrition and c
failure
HPN home parenteral nutrition
SBS short bowel syndromewater and electrolytes, such that intravenous supplementation is required to maintain health and/or
growth”.
Conclusions: This formal deﬁnition and classiﬁcation of IF, will facilitate communication and cooperation
among professionals in clinical practice, organization and management, and research.
© 2014 The Authors. Published by Elsevier Ltd and European Society for Clinical Nutrition and
Metabolism. This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/
licenses/by-nc-sa/3.0/).truction
utrition and
hronic intestinal1. Introduction
Intestinal failure (IF) was ﬁrst deﬁned in 1981 by Fleming and
Remington as “a reduction in the functioning gut mass below the
minimal amount necessary for adequate digestion and absorption
of food” [1]. IF may be due to acquired or congenital, gastrointes-
tinal or systemic, benign ormalignant diseases, whichmay affect all
age categories [2,3]. It may have an abrupt onset, or may be the
slow, progressive evolution of a chronic illness, and may be a self-
limiting short-term or a long-lasting condition (chronic intestinal
failure, CIF). Treatment of CIF relies on intestinal rehabilitation
programs that aim to restore bowel function through nutrition,
pharmacological and/or surgical therapy [4]. Patients with irre-
versible CIF are destined to need life-long home parenteral nutri-
tion (HPN) or to undergo intestinal transplantation (ITx) [5].
The deﬁnition of IF by Fleming and Remington has been revised
by other experts [2e6], but no scientiﬁc society has yet devised a
formal deﬁnition and classiﬁcation of IF. Indeed, IF is not included
in the list of PubMed Mesh terms, as failure is the term describing a
state of non functioning of organs. A PubMed search on March 15th
2014, using “intestinal failure” as general term, nonetheless
generated a total of 981 items, and showed that the number of
publications has rapidly grown in the past decades, indicating an
increased awareness of this condition (Table 1).969 1970e1979 1980e
0 20
13012 18086
7372 9420
1572 1594
9154 7892The European Society for Clinical Nutrition and Metabolism
(ESPEN) has two “special interest groups” devoted to IF, “the home
artiﬁcial nutrition and chronic intestinal failure group (HAN&CIF)”
established in 1992 and the “acute intestinal failure group (AIF)”
established in 2010 [7]. The Guideline Committee of ESPEN
committed the two groups to develop the ESPEN guidelines on IF
[8] and endorsed them to support the Guidelines with recom-
mendations on the deﬁnition and classiﬁcation of IF.2. Material and methods
The project of writing “recommendations on deﬁnition and
classiﬁcation of IF in adults” was agreed onMarch 14th 2013, with a
member of the ESPEN Guideline committee to assist the develop-
ment of the guidelines on IF, and was formally approved by the AIF
and the HAN&CIF special interest groups at their meetings held at
the ESPEN Congress in Leipzig, September 2013. All the members of
the two groups were invited to be part of the expert panel.
Theworkwas carried out between December 2013 and February
2014, using Delphi round methodology [9]. The results of the Del-
phi rounds were also discussed during the face-to-face winter
meetings of the two groups.
Each Delphi round consisted of a proposal, to which each expert
replied as “agree”, “agree, with suggested minor changes”, or
“disagree, with suggested major changes”. The ﬁrst proposal was
based on a MedLine Search, performed on 10/12/2013, for “intes-
tinal failure” AND “review”[Publication Type], which resulted in a
total of 298 articles. Only publications in English speciﬁcally dedi-
cated to the deﬁnition and classiﬁcation of IF were selected. Any
pertinent publications retrieved from the references of the selected
papers were also considered. In order to avoid duplicates, only
those articles with an “original” deﬁnition and classiﬁcation were
chosen. These initially selected papers, used as starting point for
the ﬁrst round are reported in Table 2. The subsequent proposals
were based on the collected comments as well as on any further
publications found non systematically but suggested by the ex-
perts. All the proposals were prepared and circulated by LP. The
ﬁnal consensus was reached on March 1st 2014, after 5 Delphi
rounds (on 16/12/14, 27/12/14, 19/01/14, 25/02/14 and 01/03/14)
and two live meetings (AIF 11/01/14, HAN&CIF 22/02/14). For the
purpose of the paper, the following terms were used: “oral
feeding”, to indicate the ingestion of food, “oral supplementation”1989 1990e1999 2000e2009 2010e2014 March Total
118 450 399 981
24268 39768 21790 120939
13218 30803 16811 84385
3719 6627 3382 17788
10633 13216 5805 50433
Table 2
Main original deﬁnitions and classiﬁcations of Intestinal Failure reported in the literature prior to March 15th 2014, in order of publication date. Bold characters indicate the
original contribution of each paper.
Author, date (ref) Deﬁnition and classiﬁcation of intestinal failure
Fleming CR and Remington M. 1981 [1] A reduction in the functioning gut mass below the minimum amount necessary for adequate digestion and
absorption of food
Irving M. 1995 [10] The spectrum of intestinal failure covers a wide range of diseases but essentially they can be placed in four major
categories:
short bowel syndrome, motility disorders of the bowel (chronic pseudoobstruction), small bowel parenchymaI disease,
intestinal ﬁstula
Irving M. 2000 [11] Intestinal failure can be complete or partial, the former typically following total small bowel enterectomy, whilst the
latter is seen following partial resection.
The condition can be acute and temporary, as seen with recoverable motility disorders such as ileus and obstruction, or
chronic and permanent.
Although a wide spectrum of conditions can be associated with IF, four major underlying causes can be identiﬁed.
These are: (i) the short bowel syndrome; (ii) total parenchymal bowel disease (e.g. Crohn's disease); (iii) motility
disorders, such as visceral myopathy and chronic intestinal obstruction; and (iv) small bowel ﬁstulation causing
premature loss of enteric content.
The principal resulting nutritional disorders are starvation and dehydration, but loss of body mass is frequently
made worse by catabolism from associated sepsis.
Treatment is complicated, but has at its core the provision of nutritional support, principally through the
intravenous route.
Resolution of IF can occur spontaneously by the process of intestinal adaptation.
Jeppesen PB and Mortensen PB. 2000 [12] Intestinal failure may be deﬁned by the minimum energy and wet weight absorption required to avoid home
parenteral nutrition
Patients with intestinal insufﬁciency who maintained intestinal autonomy and did not depend on parenteral
supplements
Involuntary ingestion below the minimal amount necessary to maintain nutrient and ﬂuid balance, frequently termed
oral failure, is seen in patients with pseudoobstruction and dysmotility syndromes.
Nightingale J. 2001 [13] Intestinal failure occurs ‘when there is reduced intestinal absorption so that macronutrient and/or water and
electrolyte supplements are needed to maintain health and/or growth’.
Shaffer J. 2002 [14] A novel classiﬁcation of intestinal failure was recently devised to reﬂect this:
Type I intestinal failure is classiﬁed as self-limiting intestinal failure as occurs following abdominal surgery;
Type II is intestinal failure in severely ill patients with major resections of the bowel and septic, metabolic and
nutritional complications requiring multidisciplinary intervention with metabolic and nutritional support to permit
recovery;
Type III is chronic intestinal failure requiring long-term nutritional support.
Buchman AL et al., 2003 [15] It has been suggested that intestinal failure is better deﬁned in terms of fecal energy loss rather than residual bowel
length.
However, fecal energy loss is a function of both energy intake and energy absorption. Patients who are unable to
increase their oral intake sufﬁciently or are unable to absorb sufﬁcient energy despite signiﬁcantly increased
intake, are deﬁned as patients with intestinal failure and require parenteral nutrition support.
Ding LA and Li jS. 2004 [16] Staging of intestinal failure: Acute intestinal failure, Chronic intestinal failure
Grading of intestinal failure: severe, moderate, mild
Goulet O et al., 2004 [17] Intestinal failure can be deﬁned as the reduction of functional gut mass below the minimum needed for digestion and
absorption of nutrient and ﬂuids required for maintenance in adults or growth in children. It has been suggested that IF
is better deﬁned in terms of fecal energy loss rather than residual bowel length in patients with short bowel syndrome.
Another approach is to deﬁne the degree of IF according to the amount of PN required for maintenance in adults and
growth in children
Kocoshis SA, 2004 [18] Although intestinal failure can be deﬁned by excessive fecal energy loss, a more widely accepted deﬁnition is “the
inability of the gastrointestinal tract to sustain life autonomously”.
Jeejeebhoy KN. 2005 [19] Gastrointestinal function is inadequate to maintain the nutrition and hydration of the individual without supplements
given orally or intravenously
O'Keefe SJD. 2006 [3] Intestinal failure ‘results from obstruction, dysmotility, surgical resection, congenital defect or diseaseeassociated
loss of absorption and is characterized by the inability tomaintain protein-energy, ﬂuid, electrolyte ormicronutrient
balance’
Lal S. (2006) [20] Causes of intestinal failure are varied, with self-limiting or ‘Type 1’ intestinal failure occurring relatively commonly
following abdominal surgery, necessitating short-term ﬂuid or nutritional support. The rarer, ‘Type 2’ intestinal failure,
is associated with septic, metabolic and complex nutritional complications, usually following surgical resection in
patients with Crohn's or mesenteric vascular disease.
In broad terms, intestinal failure can result from intestinal resection, inﬂammation or ﬁstulization, frommechanical
or functional intestinal obstruction, or indirectly from the effects of sepsis on the gastrointestinal tract
Messing B and Joly F [21] The recognized deﬁnition of chronic intestinal failure is a nonfunctioning small bowel either removed after severe
disease leading to very short bowel syndrome, or present but impossible to use by enteral support even accessed
through jejunostomy (eg, chronic intestinal pseudo-obstruction or extensive villous atrophy diseases).
Nightingale J and Woodward JM (2006) [22] IF may be deﬁned and quantiﬁed by balance study techniques; however, only few centres have the facilities for these
difﬁcult metabolic studies, and therefore nutrient/ﬂuid requirements determine whether IF is termed severe,
moderate, or mild. Severe is when parenteral, moderate when enteral, and mild when oral nutritional ﬂuid
supplements are needed.
Beath S et al., 2008 [23] Intestinal failure is deﬁned as the inability of the alimentary tract to digest and absorb sufﬁcient nutrients to maintain
normal ﬂuid balance, growth and health.
Gillanders L. et al., 2008 [24] Intestinal failure occurs when there is reduced intestinal absorption so that intravenous nutrients and/or water and
electrolyte supplements are needed to maintain health and/or growth. IF can be short (<1 y) or long term.
NHS National Commissioning Group for
Highly Specialised Services. 2008 [6]
Intestinal Failure comprises a group of disorders with many different causes, all of which are characterised by an
inability to maintain adequate nutrition via the intestines.
It results from obstruction, abnormal motility, major surgical resection, congenital defect or diseaseeassociated
(continued on next page)
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Table 2 (continued )
Author, date (ref) Deﬁnition and classiﬁcation of intestinal failure
loss of absorption. It is characterised not only by the inability to maintain protein-energy, but also often in difﬁculties in
maintaining water, electrolyte or micronutrient balance, particularly when there has been a major loss of length of the
small bowel. If it persists formore than a few days it demands treatment with the intravenous delivery of nutrients
and watereparenteral nutrition.
Type I e this type of Intestinal Failure is short-term, self limiting and often peri-operative in nature. Type I Intestinal
Failure is common and these patients are managed successfully in a multitude of healthcare settings, especially surgical
wards, including all units which perform major, particularly abdominal surgery. Some patients on high dependency
units (HDU) and intensive care units (ICU) will also fall into this category Care location: Wards, (HDU, ITU)
Type IIe Type II IF occurs inmetabolically unstable patients in hospital and requires prolonged parenteral nutrition over
periods of weeks or months. It is often associated with sepsis, and may be associated with renal impairment. These
patients often need the facilities of an Intensive Care or High Dependency Unit for some or much of their stay in hospital.
This type of IF is rarer and needs to be managed by a multi-professional specialist intestinal failure team. Effective
management of Type II IF can reduce the likelihood of the development of Type III Intestinal Failure. Care location: HDU,
ITU (Wards)
Type III e Type III is a chronic condition requiring long term parenteral feeding. The patient is characteristically
metabolically stable but cannot maintain his or her nutrition adequately by absorbing food or nutrients via the intestinal
tract. These are, in themain, the group of patients for which Home Parenteral Nutrition (HPN) is indicated. Care location:
Wards to home
Fishbein TM. 2009 [25] Intestinal failure refers to actual or impending loss of nutritional autonomy due to gut dysfunction. The condition is
initially managed by parenteral delivery of nutrition.
Staun M et al., 2009 [26] Intestinal failure is deﬁned as a condition with reduced intestinal absorption to the extent that macronutrient and/or
water and electrolyte supplements are needed to maintain health and/or growth. Intestinal failure is severe when
parenteral nutrition and or additional parenteral electrolytes and water are required. The condition may be
transient if gut function can be restored, but HPN is indicated for patients with chronic intestinal failure.
Rudolph A and Squires R. 2010 [27] Intestinal failure, deﬁned as an inability of a child to achieve adequate weight and growth without intravenous
nutritional support, has two principal components: the intestine is too short as a consequence of surgical resection
and the intestine is dysfunctional despite adequate length.
Gardiner KR. 2011 [28] The term intestinal failure was introduced by Fleming and Remington(1) and deﬁned as a ‘reduction in functioning gut
mass below the minimum necessary for adequate digestion and absorption of nutrients’.
Initially, this deﬁnition was used interchangeably with the need for parenteral nutrition.
Since that time the deﬁnition has been broadened and is now recognised to occur when ‘gastrointestinal function is
inadequate to maintain the nutrition and hydration of the individual without supplements given orally or
intravenously.
IF has been sub-classiﬁed into three types on the basis of duration and irreversibility.
Krawinkel MB. 2012 [29] The term “chronic intestinal failure” (CIF) refers to the body's inability to meet its energy and nutritional needs
through the gastrointestinal tract
Murray JS and Mahoney JM. 2012 [30] IF is deﬁned as the inability of the gastrointestinal system to properly function for the adequate digestion and
absorption of necessary nutrients and ﬂuids for growth and development
Other experts describe this illness as a state in which gastrointestinal function is not adequate to support sufﬁcient
growth and physiological balance in children
Pironi L. et al., 2012 [5] Intestinal failure results from reduction in the functioning gut mass characterized by the inability to maintain protein-
energy, ﬂuid, electrolyte and/or micronutrient balance.
Squires RH et al., 2012 [31] Intestinal failure in infants and children is a devastating condition that can be broadly deﬁned as the inability of the
gastrointestinal tract to sustain life without supplemental parenteral nutrition
L. Pironi et al. / Clinical Nutrition 34 (2015) 171e180174to indicate the ingestion of nutritional supplements, “enteral
nutrition” to indicate enteral tube feeding and “parenteral nutri-
tion” to indicate the intravenous infusion of nutritional admixtures
or of water and electrolyte solutions.
The deﬁnitive recommendations consist in the “deﬁnition of IF”,
a “functional classiﬁcation of IF”, a “pathophysiological classiﬁca-
tion of IF” and a “clinical classiﬁcation of chronic IF”.
As there were no published data available to serve as a starting
point for a “clinical classiﬁcation”, this was developed on the basis
of the common experience of the panel experts. The applicability of
the devised “clinical classiﬁcation” was veriﬁed on two samples of
randomly selected patients, currently on HPN for CIF due to either
benign or active malignant disease. This consisted in a cross-
sectional investigation of the energy content and volume of the
parenteral nutrition admixture of 114 patients cared for at the
Center for Benign Chronic Intestinal Failure of the S. Orsola-
Malpighi University Hospital, Bologna (Italy) and of 50 patients
with active cancer cared for at the Tumor Biology Center, Albert-
Ludwigs-University, Freiburg (Germany).
3. Results
The deﬁnition and classiﬁcation of IF are reported and discussed
below and are summarized in Table 3. Table 4 summarizes thepathophysiological mechanisms of IF. The diseases that may
determine an IF are listed in Table 5.
3.1. Deﬁnition of intestinal failure
Intestinal failure is deﬁned as the reduction of gut function below
the minimum necessary for the absorption of macronutrients and/or
water and electrolytes, such that intravenous supplementation is
required to maintain health and/or growth.
The reduction of gut absorptive function that doesn't require
intravenous supplementation to maintain health and/or growth, can
be considered as “intestinal insufﬁciency” (or “intestinal deﬁciency” for
those languages where “insufﬁciency” and “failure” have the same
meaning).
The panel identiﬁed IF as a “state of non-functioning”, where the
gut function referred to was the “absorption of proteins, lipids,
carbohydrates, water and electrolytes” [12,13,15,24,29,30], and the
“threshold for loss of function” was the “need for intravenous
supplementation” to maintain health and/or growth
[6,12e14,21,24,31]. For this purpose, the original deﬁnition by
Fleming and Remington was modiﬁed by deleting the term “mass”,
identifying “absorption” as the key gut function, replacing the term
“food” with “macronutrients and/or water and electrolytes”, and by
specifying the “need for intravenous supplementation to maintain
Table 3
ESPEN recommendations: deﬁnition and classiﬁcation of intestinal failure.
Deﬁnition
Intestinal failure is deﬁned as the reduction of gut function below the
minimum necessary for the absorption of macronutrients and/or water
and electrolytes, such that intravenous supplementation is required to
maintain health and/or growth.
The reduction of gut absorptive function that doesn't require intravenous
supplementation to maintain health and/or growth, can be considered as
“intestinal insufﬁciency” (or “intestinal deﬁciency” for those languages where
“insufﬁciency” and “failure” have the same meaning).
Functional classiﬁcation
On the basis of onset, metabolic and expected outcome criteria, intestinal failure
is classiﬁed as:
 Type I e acute, short-term and usually self limiting condition
 Type II e prolonged acute condition, often in metabolically unstable
patients, requiring complex multi-disciplinary care and intravenous
supplementation over periods of weeks or months
 Type III e chronic condition, in metabolically stable patients, requiring
intravenous supplementation over months or years. It may be reversible or
irreversible.
Pathophysiological classiﬁcation
Intestinal failure can be classiﬁed into ﬁve major pathophysiological conditions,
which may originate from various gastrointestinal or systemic diseases:
 short bowel
 intestinal ﬁstula
 intestinal dysmotility
 mechanical obstruction
 extensive small bowel mucosal disease
Clinical classiﬁcation of chronic intestinal failure
On the basis of the requirements for energy and the volume of the intravenous
supplementation (IV), chronic intestinal failure is categorized into 16 subtypes
IV energy
supplementationb
(kcal/kg Body
Weight)
Volume of the IV supplementationa
(ml)
1000
[1]
1001e2000
[2]
2001e3000
[3]
>3000
[4]
0 (A) A1 A2 A3 A4
1e10 (B) B1 B2 B3 B4
11e20 (C) C1 C2 C3 C4
> 20 (D) D1 D2 D3 D4
a calculated as daily mean of the total volume infused per week ¼ (volume per
day of infusion x number of infusions per week)/7.
b calculated as daily mean of the total energy infused per week ¼ (energy per
day of infusion x number of infusions per week)/7.
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techniques, comparing nutrient requirement with nutrient ab-
sorption, would be the optimal way to identify and quantify IF in
the individual patient [12]. However, considering that very few
centres have the facilities for these difﬁcult metabolic studies, the
requirement of intravenous nutrient/ﬂuid supplementation was
used as a “surrogate diagnostic criterion”. The exclusive need for
intravenous supplementation was the most debated issue, because
some previous deﬁnitions of IF included also oral supplementation
and enteral nutrition [2,5,6,11,18,19,22,23,25,26,28]. Micronutrients
were not mentioned in the deﬁnition in order to avoid any
misunderstanding about impaired gut absorption resulting in
micronutrient deﬁciency alone, as this would not be considered as
IF [2,5,6].
The proposed deﬁnition indicates that for the diagnosis of IF
two criteria must be simultaneously present: a “decreased ab-
sorption of macronutrients and/or water and electrolytes due to a
loss of gut function” and the “need for intravenous supplemen-
tation”. This facilitates an understanding of which conditions
cannot be considered IF because only one criterion is present:
patients with reduced food intake but normal gut function, like
those with disease-related hypophagia, or with anorexia nervosa
or any other psychiatric disorders; patients with altered gut
function but conserved intestinal absorption, like neurological or
cancer patients with impaired swallowing or dysphagia; patients,especially children, with active Crohn's disease treated by enteral
nutrition; patients treated by parenteral nutrition because of
refusal of otherwise effective enteral nutrition; patients with a
reduction of gut function impairing intestinal absorption but in
whom health and growth can be maintained by oral supple-
mentation, enteral nutrition, re-feeding enteroclysis (reinfusion of
chyme to the distal limb of a high output small bowel ﬁstula), or
those who require only vitamins and trace element supplemen-
tation. For these last conditions, the panel proposes that the term
“intestinal insufﬁciency or intestinal deﬁciency” could be
considered [12]. The alternative between “insufﬁciency” and
“deﬁciency” has been included to allow an appropriate translation
in those languages where “insufﬁciency” and “failure” have the
same meaning, such as in French, Italian and other Latin
languages.
3.2. Functional classiﬁcation
On the basis of onset, metabolic and expected outcome criteria, IF is
classiﬁed as
▪ Type I e acute, short-term and usually self limiting condition
▪ Type II e prolonged acute condition, often in metabolically un-
stable patients, requiring complex multi-disciplinary care and
intravenous supplementation over periods of weeks or months
▪ Type III e chronic condition, in metabolically stable patients,
requiring intravenous supplementation over months or years. It
may be reversible or irreversible
This classiﬁcation, termed “functional”, was also used in the UK
project “A Strategic Framework for Intestinal Failure and Home
Parenteral Nutrition Services for Adults in England” [6], and was
ﬁrst described in 2002 [14]. It aims to categorize the medical care,
the professional expertise, the management, the treatment setting
as well as the organization, logistic and administrative issues
required for the treatment of IF.
Acute type I and type II IF have been extensively reviewed
[20,28]. Type I IF is a common, short and often self limiting, con-
dition, estimated to occur in about 15% patients in the peri-
operative setting after abdominal surgery or in association with
critical illnesses such as head injury, pneumonia and acute
pancreatitis. While intestinal function recovers, short-term paren-
teral ﬂuid and nutrition support can be required. Post-operative
ileus usually spontaneously resolves within a few days. This dura-
tion can be shortened by multimodal enhanced recovery tech-
niques aiming to promote early mobilization and early introduction
of oral nutrition [32]. Such patients are usually managed in surgical
wards, although some patients in critical care environments also ﬁt
into this category.
Type II IF is an uncommon condition, most often seen in the
setting of an intra-abdominal catastrophe (like peritonitis due to
visceral injury) and is almost always associated with septic, meta-
bolic and complex nutritional complications. Renal impairment
may be present. It is originally an acute event, often occurring in a
previously healthy subject (mesenteric ischaemia, volvulus or
abdominal trauma) or complicating intestinal surgery (anastomotic
leak; inadvertent and unrecognized intestinal injury) and necessi-
tating massive enterectomy and/or resulting in one or more
enterocutaneous ﬁstulae, with or without a proximal stoma. Less
frequently, it may be the complication of a type III chronic IF, rep-
resenting a condition of “acute on chronic” IF. Type II IF requires
prolonged parenteral nutrition over periods of weeks or months.
These patients often initially need the facilities of an intensive care
or high dependency unit and to bemanaged by amulti-professional
specialist IF team for part or most of their stay in hospital. Using a
Table 4
Pathophysiological classiﬁcation of intestinal failure.
Condition Primary mechanism of intestinal failure Concomitant mechanisms
Short bowel Reduced absorptive mucosal surface  Increased intestinal losses of ﬂuids and electrolytes (adjunctive
mechanism in the case of end-jejunostomy)
 Restricted oral/enteral nutrition (to reduce intestinal losses)
 Disease-related hypophagia
 Lack of adaptive hyperphagia
 Accelerated gastrointestinal transit time
 Small bowel bacterial overgrowth
Intestinal ﬁstula By pass of large areas of absorptive mucosal surface  Increased intestinal losses of ﬂuids and electrolytes
 Disruption of the enteroehepatic cycle
 Restricted oral/enteral nutrition or total fasting (bowel rest) to
decrease ﬁstula output
 Impaired intestinal peristalsis and increased metabolic demand
related to concomitant sepsis and inﬂammation
Intestinal dysmotility Restricted oral/enteral nutrition or total fasting from intolerance
due to feeding-related exacerbation of digestive symptoms or to
episodes of non-mechanical intestinal obstruction
 Malabsorption due to small bowel bacterial overgrowth
 Increased intestinal secretion of ﬂuids and electrolytes in the
obstructed segments
 Increased intestinal losses of ﬂuids and electrolytes due to
vomiting, gastric drainage and/or diarrhoea
Mechanical obstruction Incomplete or total fasting (bowel rest)  Increased intestinal secretion of ﬂuids and electrolytes in the
obstructed segments
 Increased intestinal losses of ﬂuids and electrolytes with
vomiting or gastric drainage
Extensive small
bowel mucosal
disease
Inefﬁcient absorptive and/or nutrient losing mucosal surface.  Increased intestinal losses of ﬂuids and electrolytes
 Restricted oral/enteral nutrition
 Disease-related hypophagia
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rogatemarker, the annual incidence of Type II IF has been estimated
to be 9 patients per million population [6]. Outcome is most
frequently represented by full intestinal rehabilitation (about 40%),
enteral nutrition including distal feeding (10%) or type III IF
requiring prolonged HPN (50%). An in-hospital mortality as high as
9.6%e13% has been reported. In the majority of deaths the under-
lying process is sepsis, which can be intra-abdominal but distant
sites such as bone, cardiac and the central nervous system as well as
the intravenous feeding catheter have all been implicated.
Specialist inepatient intestinal failure units, with multi-
disciplinary teams are recommended [33e35].
Type III IF is a chronic condition (CIF) in a metabolically stable
patient, which usually requires long-term HPN. CIF may be the
evolution of a type II acute IF, the result of progressive and devas-
tating gastrointestinal or systemic benign diseases, often requiring
multiple intestinal resections (such as Crohn's disease, radiation
enteritis, familiar polyposis, chronic intestinal pseudo-obstruction,
intestinal lymphangectasia, or systemic sclerosis), the main clinical
feature of congenital digestive diseases (such as gastroschisis, in-
testinal atresia, microvillous inclusion disease and intestinal
epithelial dysplasia), or the end stage of intra-abdominal or pelvic
cancer [5,36].
CIF due to benign disease may be a reversible condition.
Weaning from HPN after 1e2 years of starting may occur in 20%e
50% of the patients, depending on the characteristics of the CIF [5].
Patients with CIF due to benign disease have a high probability of
long-term survival on HPN (about 80% in adults and 90% in children
at 5 years) [5]. Overall, about two thirds of patientsmay have partial
or total social and working rehabilitation as well as a good family
life [37e39]. On the other hand, CIF may be associated with life-
threatening complications and the condition itself may be highly
disabling and impairs the quality of life [5,23]. Treatment of CIF is
based on complex technologies and requires multidisciplinary and
multiprofessional activity and expertise [23]. The outcome of pa-
tients with benign CIF, in terms of reversibility, treatment-related
morbidity and mortality, and survival probability is strongly
dependent on care and support from an expert specialist team
[5,23]. Patients with irreversible CIF are destined to need life-longHPN or ITx. On the basis of data on safety and efﬁcacy, HPN is
considered the primary treatment for CIF, whereas ITx is reserved
for those patients at risk of death because of life-threatening
complications related to HPN or to the underlying gastrointestinal
disease [5]. In Europe, the prevalence of HPN for CIF due to benign
disease has been estimated to range from 5 to 20 cases per million
population [36,40e43]. CIF due to benign disease has been
included in the 2013 Orphanet list of rare diseases [44].
Treatmentwith HPN for CIF due to end stagemalignant disease is
controversial [45,46]. HPN patients with cancer varies from 60% in
Italy to 20e30% in Spain, France and Belgium, and only 8% in UK
[36,40e43]. This wide range may be due to different medical and
social attitudes toward palliative care. Other factors that play a role
include different regulation and funding of the various national
health care systems and/or to the inappropriate use of a central
venous catheter, previously positioned for chemotherapy.Many such
patients could be adequately managed by enteral nutrition. Overall,
the scientiﬁc society guidelines have not recommended HPN for
patients with a short life expectancy due to the malignancy (gener-
ally considered inappropriate if this is less than 2e3 months) [47].
3.3. Pathophysiological classiﬁcation
If can be classiﬁed into ﬁve major pathophysiological conditions,
which may originate from various gastrointestinal or systemic
diseases:
▪ short bowel
▪ intestinal ﬁstula
▪ intestinal dysmotility
▪ mechanical obstruction
▪ extensive small bowel mucosal disease
The ﬁrst classiﬁcation of IF, based on the underlying causes, was
described in 1991 [33] and further developed in 1995 [10,11], 2006
[2,20], 2008 [6] and 2010 [27]. The panel has termed this classiﬁ-
cation “pathophysiological”, to underline the main mechanisms
that, alone or in association, can determine the development of an
IF (Table 4).
Table 5
Gastrointestinal or systemic diseases that may determine the pathophysiological
conditions of intestinal failure. The list may not be exhaustive of all the possible
causes.
Condition Most frequent underlying diseases
Short bowel Extensive surgical resection for:
 Mesenteric infarction (arterial or venous thrombosis)
 Crohn's disease
 Radiation enteritis
 Surgical complications
 Intestinal volvulus
 Familial polyposis
 Abdominal trauma
 Intestinal angiomatosis
 Necrotizing enterocolitis
 Complicated intussusception
Congenital:
 Gastroschisis
 Intestinal atresia
 Intestinal malformation
 Omphalocoele
Intestinal ﬁstula  Inﬂammatory (Crohn's disease, diverticular disease,
pancreatic disease, radiation enteritis)
 Neoplastic (colon cancer, ovarian cancer, small bowel
malignancy)
 Iatrogenic (operation, percutaneous drainage)
 Infectious disease (tuberculosis, actinomycosis)
 Trauma
 Foreign body
Intestinal
dysmotility
Acute: post-operative, systemic inﬂammatory or
neurological reaction associated with critical illnesses;
Ogilvie syndrome (acute colonic non-mechanical
obstruction)
Chronic Intestinal Pseudo-Obstruction (obstructive
symptoms for at least 6 months):
 Primary/idiopathic (with no underlying disorder)
 Neuropathic: inﬂammatory or degenerative injury to
the enteric nervous system (ENS)
 Myopathic: damage of the smooth muscle (congenital,
familial, or sporadic); familial visceral myopathy is
classiﬁed as type 1 (autosomal dominant), type 2
(autosomal recessive with associated ptosis and oph-
thalmoplegia), or type 3 (autosomal recessive with the
presence of gastrointestinal tract dilatation)
 Mesenchymopathy: injury of the interstitial cells of
Cajal
 Secondary (due to an underlying disorder); may be also
classiﬁed as neuropathy, myopathy or mesenchymopathy
 Collagen vascular diseases: primary systemic sclerosis,
systemic lupus erythematosus, dermatomyositis/
polymyositis, periarteritis nodosa, rheumatoid
arthritis, mixed connective tissue disorders, Ehlers-
Danlos syndrome
 Endocrine disorders: diabetes, hypothyroidism, hy-
poparathyroidism, hyperparathyroidism
 Neurologic disorders: Parkinson disease, Alzheimer
disease, Shy-Drager syndrome, Chagas disease,
Hirschsprung disease (intestinal hypoganglionosis),
dysautonomia (familial or sporadic), Von
Recklinghausen's disease
 Medication associated: tricyclic antidepressants, anti-
cholinergic agents, ganglionic blockers, anti-
Parkinsonian agents, clonidine, phenothiazines
 Paraneoplastic: central nervous system neoplasms, lung
microcytoma, brochial carcinoid, leiomyosarcomas,
carcinoid, thymoma
 Miscellaneous: celiac disease, inﬁltrative disorders
(amyloidosis, lymphoma), alcohol abuse, post-
infectious processes (viral, bacterial, parasitic), radia-
tion, vascular insufﬁciency, metabolic (hypokalaemia,
hypomagnesemia), postsurgical, posteorgan trans-
plant, mitochondrial disorders
Mechanical
obstruction
 Obturation (polypoid tumors, intussusception, gallstones,
foreign bodies, bezoars, feces)
 Intrinsic bowel lesions (stenosis or strictures: neoplastic,
inﬂammatory bowel disease, chemical, anastomotic)
Table 5 (continued )
Condition Most frequent underlying diseases
 Extrinsic lesions (abdominal adhesions: previous surgery,
previous peritonitis, frozen abdomen; hernias; neoplasia:
desmoid tumors, peritoneal carcinomatosis; volvulus;
congenital bands)
Extensive small
bowel mucosal
disease
 Microvillous inclusion disease (or microvillous atrophy)
 Tufting enteropathy (or intestinal epithelial dysplasia)
 Tricho-hepato-enteric syndrome (or syndromic diarrhoea
or phenotypic diarrhoea)
 Intractable diarrhea of infancy
 Severe food allergy in children
 Autoimmune enteropathy
 Intestinal lymphangectasia
 Waldman disease and other protein-losing enteropathies
 Common variable immunodeﬁciency
 Crohn's disease
 Celiac disease
 Radiation enteritis
 Chemotherapy related enteritis
 Congenital diseases (such as glucose-galactose
malabsorption, congenital defects of glycosylation,
primary bile acid malabsorption, chloride diarrhea,
sodium diarrhoea)
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or of congenital diseases of the small intestine (Table 5). In adults,
normal small intestinal length, measured from the duodenojejunal
ﬂexure at autopsy or surgery, varies from about 275 cm to 850 cm
[15,22,48]. The clinical feature associated with a remaining small
bowel in continuity (even though the total small bowel length
including that bypassed may be normal) of less than 200 cm is
deﬁned as short bowel syndrome (SBS) [15,22]. SBS has been re-
ported to be the main cause of type III CIF, accounting for about 75%
of adults and 50% of children on HPN in Europe [36].
The primary pathophysiological mechanism of IF in the patient
with SBS is the reduced intestinal absorptive surface area (Table 4).
The likelihood of developing an SBS-associated IF depends on the
residual small bowel length in continuity and on several
“concomitant pathophysiological mechanisms” related to the
anatomy, integrity, function and adaptive potential of the small
bowel remnant as well as to the underlying clinical condition
[15,22,49]. The post-resection intestinal adaptation is a sponta-
neous process that attempts to ensure a more efﬁcient absorption
of nutrients per unit length of the remaining bowel [15,22]. This
occurs partly by increasing the absorptive area (structural adapta-
tion) and/or by slowing the gastrointestinal transit (functional
adaptation). It is promoted by the presence of nutrients in the gut
lumen, by the pancreatic and biliary secretions and by gut hor-
mones mainly produced by the ileum and colon, and usually takes
place over 1 or 2 years. Post-operative intestinal adaptation appears
to be absent or impaired in the presence of an end-jejunostomy
[15,22].
In adults, a high risk for developing IF due to inadequate length
of small bowel in continuity has been reported when there is less
than 35 cm small bowel with a jejunoileal anastomosis with an
intact colon, less than 60 cm small bowel with a jejunocolic anas-
tomosis or less than 115 cm small bowel with an end-jejunostomy
[22]. Other mechanisms contributing to IF may be, excessive ﬂuid
and electrolyte intestinal losses in the presence of an end jeju-
nostomy, restriction of oral nutrient intake in an attempt to
decrease the intestinal losses, reduced oral intake because of un-
derlying disease-related hypophagia and failure to develop the
post-resection adaptive hyperphagia [22,49].
SBS-associated IF may be reversible because of the intestinal
adaptation process and/or intestinal rehabilitation programs [4]
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weaning off HPN has been reported to be about 50% in adults and
up to 73% in children. Complete weaning off HPN in patients with
SBS is unlikely (<10%) to occur after 2e3 years have elapsed since
the most recent intestinal resection [5,50,51].
Intestinal ﬁstulas are abnormal communications between two
parts of the gastrointestinal tract, between the gut and the other
organs (eg the bladder), or between the gastrointestinal tract and
the skin (enterocutaneous ﬁstulas, EC) [10,34,35,52e54]. About
75e85% of EC ﬁstulas form after surgery as a result of bowel injury,
inadvertent enterotomy and/or anastomotic leakage, in the pres-
ence of malignancy or inﬂammatory bowel disease, and with
attempted surgical division of dense adhesions. In the remaining
15e25%, EC ﬁstulas form spontaneously secondary to underlying
pathology, in particular Crohn's disease. Other causes include ra-
diation enteritis, diverticular disease, malignancy, intra-abdominal
sepsis and trauma. Anatomically, an EC ﬁstula is identiﬁed by the
segment of the gut from which it originates (eg, gastrocutaneous,
enterocutaneous) (Table 5). EC ﬁstulas are classiﬁed by their aeti-
ology, anatomy and output volume. In general, a ﬁstula with an
output >500 mL/day in the fasting state is generally regarded as a
high output ﬁstula [55].
In EC ﬁstulas, the enteric content is prematurely lost from the
small bowel lumen. The primary mechanism of IF is the bypass of a
large area of intestinal absorption surface [10,34,35,52e55], a
condition resembling a short bowel (Table 4). The onset of an EC
ﬁstula is often an acute event, associated with intra-abdominal
abscess collection, systemic sepsis and the related metabolic
derangement, as well as with high intestinal ﬂuid and electrolyte
losses with the ﬁstula efﬂuent. Exposure of the skin around the
ﬁstula to the corrosive effect of the enteric content can lead to rapid
tissue breakdown in this area and may be a major treatment
challenge. Concomitant pathophysiological mechanisms contrib-
uting to EC ﬁstula-associated IF may be the impairment of gastro-
intestinal motility and the metabolic alterations associated with
systemic sepsis or intra-abdominal inﬂammation, the excessive
intestinal losses of ﬂuids and electrolytes, the disruption of the
enteroehepatic cycle of bile acids, and the restricted or abolished
(“bowel rest”) oral/enteral nutrition to decrease the ﬁstula output
and/or to favor spontaneous ﬁstula closure.
In adults, EC ﬁstulas are among themost common causes of type
II, prolonged acute IF. Parenteral nutrition has a key role in the early
days of treatment, often characterized by metabolic instability.
When metabolic stability has been achieved, nutrition support
through ﬁstuloclysis [56] or re-feeding enteroclysis [57] may be
attempted, when a double enterostomy is present. In this case there
are a proximal stoma representing the EC ﬁstula or a surgically
placed transient enterostomy and a distal stoma representing the
intestine segment totally excluded from the chime transit. Fistu-
loclysis is a method of enteral nutrition through the intestine distal
to the ﬁstula. Re-feeding enteroclysis consists in chyme collection
from the proximal stoma and re-infusion down the distal stoma.
Fistuloclysis and re-feeding enteroclysis may allow weaning off
parenteral nutrition and intravenous electrolyte supplementation
[56,57]. As a consequence the underlying intestinal derangement
passes from IF to intestinal insufﬁciency/deﬁciency. Nevertheless,
EC ﬁstulas account for about 2% of patients with reversible type III
IF, requiring intravenous supplementation in hospital or at home
for a period of 3e12 months before undergoing planned recon-
structive surgery [36].
The term intestinal dysmotility is used to indicate the presence
of disorders of the propulsion of the gut content in the absence of
ﬁxed occluding lesions. It may be loco-regional, affecting only one
bowel segment, as in achalasia, gastroparesis, colonic obstruction
and Hirschprungs' disease, or multi-regional, involving more thanone part of the GI tract, especially the small bowel. Acute intestinal
dysmotility is the primary pathophysiological cause of type I IF due
to post-operative or acute critical illness associated ileus, and a
frequent concomitant cause of type II IF, due to the impaired
gastrointestinal motility associated with systemic or intra-
abdominal inﬂammation. Permanent intestinal dysmotility is
termed chronic intestinal pseudo-obstruction (CIPO), where the
modiﬁer “pseudo” is used to underline the absence of occluding
lesions [58e60].
CIPO may be congenital or acquired (Table 5). Congenital dis-
orders can be sporadic or familial. Acquired forms can be sec-
ondary to a variety of insults, such as infections, autoimmune
processes, mitochondrial dysfunction, and side effects of medica-
tions. However in the majority of cases, CIPO is an idiopathic
disorder of unknown aetiology. Acquired forms are more prevalent
in adults, while congenital forms predominate in children.
Whatever the underlying cause, CIPO can be subdivided histo-
logically into 3 categories: neuropathies (involving the enteric
nervous system and/or the autonomic nervous system, either the
sympathetic or parasympathetic), myopathies (involving the
smooth muscle), or mesenchymopathies (involving the interstitial
cells of Cajal). Some patients may have other coexisting pathology
[58e60].
In intestinal dysmotility, the primary pathophysiological
mechanism is intolerance to oral or enteral nutrition resulting in
inadequate nutritional intake. The mucosal surface is generally
intact (Table 4). “Secondary pathophysiological mechanisms”
include nutrient malabsorption due to small bowel bacterial over-
growth, and increased intestinal secretion and/or losses of ﬂuids
and electrolytes, occurring in the dilated bowel segments, or after
intestinal resection and venting or end-ostomy performed to
relieve symptoms. CIPO-associated IF represents approximately
20% of both adults and children on HPN for type III chronic IF [36].
The reversibility of IF in patients with CIPO is lower than that re-
ported in SBS, having been reported in 25e50% in adults and
25e38% in children, with a 78% 5 year survival probability for adults
on HPN [5,51,61].
Mechanical obstruction of the intestinal lumen results from a
physical abnormality affecting the intestine, which may be intra-
luminal, intrinsic or extrinsic, of benign or malignant origin
(Table 5). It may be an acute event encompassing a feature of type I
IF, that resolves in a few days through conservative medical treat-
ment or a surgical procedure. It may also be a prolonged feature,
determining a type II or III IF, as in patients with extensive adhe-
sions (“frozen abdomen”), or in those with peritoneal carcinoma-
tosis associated with late-stage intra-abdominal malignancy. The
primary pathophysiological mechanism of IF in obstruction is the
spontaneous or prescribed (“bowel rest”) abolished oral or enteral
nutrition (Table 4). Secondary mechanisms include the increased
intestinal secretion of ﬂuids and electrolytes in the obstructed
segment, and increased intestinal losses of ﬂuids and electrolytes
with vomiting or naso-gastric drainage.
Extensive small bowel mucosal disease indicates a condition
characterized by an intact or almost intact, although inefﬁcient,
mucosal surface [3,5,17] (Table 5). The reduction of nutrient ab-
sorption and/or the loss of nutrients through the intestinal mucosa
to the point where the body's requirements are no longer met, are
the most frequent primary mechanisms of IF (Table 4). Rarely,
increased intestinal secretion of ﬂuids and electrolytes can be
present as a concomitant mechanism. The most frequent diseases
causing extensive mucosal damage are reported in Table 5. Exten-
sive small bowel mucosal disease has been reported to be the cause
of CIF in about 25% of children and 5% of adult patients on long term
HPN. In adults with type III IF due to extensive mucosal disease,
weaning from HPN rarely occurs [5,51].
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On the basis of the requirements for energy and the volume of
the intravenous supplementation, IF can be categorized into 16
subtypesIV energy supplementationb
(kcal/kg Body Weight)
Volume of the IV supplementationa (ml)
1000
[1]
1001e2000
[2]
2001e3000
[3]
>3000
[4]
0 (A) A1 A2 A3 A4
1e10 (B) B1 B2 B3 B4
11e20 (C) C1 C2 C3 C4
> 20 (D) D1 D2 D3 D4
a Calculated as daily mean of the total volume infused per week ¼ (volume per
day of infusion x number of infusions per week)/7.
b Calculated as daily mean of the total energy infused per week¼ (energy per day
of infusion x number of infusions per week)/7.The panel discussed the need for and the feasibility of a severity
classiﬁcation of IF, as for failure of the other organs. Unfortunately,
there are no simple indicators of the degree of intestinal absorption
and/or metabolic balance. Therefore, a “general classiﬁcation of the
severity of IF” could not be devised. In addition, the severity of the
clinical picture of the individual patient can be inﬂuenced by a
number of extra-intestinal factors, including the metabol-
iceinﬂammatory reaction, nutritional compromise, abdominal and
systemic lesions and symptoms, the response to treatments, as well
as psycho-social factors. Therefore, a severity classiﬁcation should
be deﬁned for each individual functional and/or pathophysiological
cause of IF, as already described for EC ﬁstulas [34,52e54], SBS
[15,23,62] and CIPO [58e60].
However, the panel agreed on the need for a “clinical classiﬁ-
cation” of IF, aiming to facilitate communication and cooperation
among professionals through a more objective categorization of
patients, to be used in clinical practice, management/administra-
tive organization, epidemiological surveys and clinical research.
Considering that no published data were available to be used as a
starting point, the development of a “clinical classiﬁcation” was
based on the common experience of the panel of experts.
Furthermore, because of the already mentioned difﬁculty in sum-
mating the many variables that could play a role in the individualTable 6
Clinical classiﬁcation of adult patients on home parenteral nutrition for chronic
intestinal failure due to benign disease (a) or to active cancer (b).
IV energy supplementationb
(kcal/kg Body Weight)
Volume of the IV supplementationa (ml)
 1000
[1]
1001e2000
[2]
2001e3000
[3]
> 3000
[4]
a) Distribution of the patients with CIF due to benign disease (n ¼ 114; mean
age±standard deviation: 47.2 ± 15.5 years; pathophysiology of IF: short
bowel 65, entero-cutaneous ﬁstula 10, intestinal dysmotility 29, extensive
small bowel mucosal disease 10)
0 (A) 2
1e10 (B) 6 4 2
11e20 (C) 9 10 10 2
> 20 (D) 2 37 20 10
b) Distribution of the patients with CIF due to active cancer (n ¼ 50; mean
age±standard deviation: 62.4 ± 12.6 years; pathophysiology of IF:
mechanical occlusion 39; intestinal dysmotility, 11)
0 (A)
1e10 (B) 5
11e20 (C) 12 6
>20 (D) 3 21 3
a Calculated as daily mean of the total volume infused per week ¼ (volume per
day of infusion x number of infusions per week)/7.
b Calculated as daily mean of the total energy infused per week¼ (energy per day
of infusion x number of infusions per week)/7.patient, the panel decided to devise a clinical classiﬁcation only for
type III CIF, because of the greater metabolic stability and the longer
duration of this condition than expected in types I and II IF.
Starting from the given deﬁnition of IF, the panel reached a
consensus on a “clinical classiﬁcation of chronic IF” based on the
intravenous “energy and volume” requirements. As it is not truly a
severity classiﬁcation, the panel emphasize that this has no impli-
cation in the level of optimization of care required by the patients,
which must be the same for all the patients regardless of their
classiﬁcation.
Table 6 reports the results of the cross sectional investigation on
two samples of randomly selected patients, currently on HPN for
type III CIF due to either benign or active malignant disease, which
aimed to verify the applicability of the clinical classiﬁcation. As
expected, almost all the categories were represented, with the
exception of the rather unusual, though not improbable, re-
quirements of high volume of ﬂuid and electrolytes with no or
minimal energy (categories B4 and A2-A4). The range of the patient
distributionwithin the categories of the “clinical classiﬁcation” was
wider in CIF for benign disease than in CIF for active cancer. This
was in agreement with the different causes, clinical features and
expected outcomes of the two patient populations. Patients with
benign disease have greater variability in the pathophysiological
causes of IF and of activity-related energy expenditure, the last
being dependent on the degree of physical rehabilitation. In pa-
tients with active cancer, intestinal dysmotility or mechanical
obstruction due to the cancer are the most frequent causes of the IF,
and physical activity is often limited to a chair-to-bed life. Allowing
a simple and easy-to-do categorization of patients with CIF, the
proposed “clinical classiﬁcation” should facilitate communication
and cooperation among professionals. The panel recognizes the
need for prospective studies to investigate its potential prognostic
value.
4. Conclusions
IF is awell recognized organ failure, but no formal deﬁnition and
classiﬁcation of IF had been devised before. These ESPEN endorsed
recommendations on “deﬁnition and classiﬁcation of IF in adults”
(Table 3) aims to facilitate communication and cooperation among
professionals in clinical practice, organization, management and
research.
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